4DMedical has secured a new partnership with the University of Chicago Medicine (UChicago Medicine), a leading academic medical centre in the United States.
The agreement will allow UChicago Medicine clinicians to utilise 4DMedical’s advanced portfolio of structural and functional lung imaging products, including the CT LVAS technology.
This collaboration is expected to enhance the hospital’s ability to diagnose and manage complex lung conditions with unparalleled precision, reinforcing UChicago Medicine’s reputation as a leader in pulmonary care innovation.
Dr Kyle Hogarth, a renowned pulmonologist and director of bronchoscopy at UChicago Medicine, expressed strong support for the partnership, noting that the integration of 4DMedical’s technology will maximise the information obtained from chest CT scans.
“We have always wanted to maximise the CT scan for the sake of our patients – to make the most of the radiation we have used. With the addition of CT LVAS™ and other products, we believe we have taken the next step,” said Dr Hogarth.
This deal further strengthens 4DMedical’s presence in the US healthcare market, positioning its imaging solutions as key tools for clinical decision-making.
The contract with UChicago Medicine, which is set to extend for a 12-month renewable term, follows the company’s recent momentum in securing partnerships with other leading U medical institutions, including UCSD Health.
4DMedical also announced the expansion of its partnership with UCSD Health, which now includes SeleCT, a screening service designed to identify patients suitable for treatment with endobronchial valves.
Dr Jonathon Chung, a radiologist at UCSD Health, emphasized the value of 4DMedical’s algorithms in diagnosing chronic lung diseases and improving healthcare outcomes.
He noted that these tools will help screen for conditions such as emphysema, pulmonary fibrosis, and coronary artery disease, making every imaging encounter a valuable opportunity for early intervention.
Andreas Fouras, MD/CEO and founder of 4DMedical, commented on the strategic significance of the new contracts, stating that the expansion with UChicago Medicine and UCSD Health showcases the growing recognition of the company’s innovative technology in transforming respiratory care.
“This contract, in combination with the immediate growth in contract value from UCSD Health, clearly demonstrates the demand for our comprehensive portfolio of products,” said Fouras.
